DRG Market Assessment reports

Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…

Because of the dearth of targeted treatments in China, patients with relapsed/refractory (R/R) NHL, multiple myeloma, or ALL continue to be prescribed salvage chemotherapy in later lines of…

Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence there. Traditionally, patients suffering…

China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…

Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly…

Clarivate publishes content on Angelman syndrome and its current and future management, patient journey, and the competitive landscape in the U.S., EU5, and China markets between 2021 and 2031

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in China and, thus, a major public health concern. We expect the Chinese COPD therapy market to experience robust…

Executive Insights report on current medical practice, unmet need, and emerging treatments for spinocerebellar ataxia in the United States, Europe, and China.

Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of…

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…